Alaunos Therapeutics (TCRT) Share-based Compensation (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Share-based Compensation came in at $141000.0 in Q1 2026, up 107.35% YoY from $68000.0 in Q1 2025, and up 201.44% on a QoQ basis from -$139000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Share-based Compensation (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 18 years of Share-based Compensation data on file, last reported at $141000.0 in Q1 2026.
- Quarterly Share-based Compensation rose 107.35% year-over-year to $141000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $487000.0 (up 47.58% YoY) and the FY2025 annual result came in at $414000.0, down 4.83% from the prior year.
- Share-based Compensation improved to $141000.0 in Q1 2026, from -$139000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $990000.0 in Q2 2022 to a low of -$139000.0 in Q4 2025.
- A 5-year average of $430411.8 and a median of $250000.0 in 2023 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 276.25% in 2025, down 271.6% in 2025.
- Tracing TCRT's Share-based Compensation over 5 years: stood at $877000.0 in 2022, then slumped by 71.49% to $250000.0 in 2023, then plunged by 67.6% to $81000.0 in 2024, then sank by 271.6% to -$139000.0 in 2025, then soared by 201.44% to $141000.0 in 2026.
- The last three Share-based Compensation figures came in at $141000.0 (Q1 2026), -$139000.0 (Q4 2025), and $301000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | 246,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 141,000.00 |
| Mar 31, 2026 | 141,000.00 |
| Dec 31, 2025 | -139,000.00 |
| Dec 31, 2025 | -139,000.00 |
| Sep 30, 2025 | 301,000.00 |
| Sep 30, 2025 | 301,000.00 |
| Jun 30, 2025 | 184,000.00 |
| Jun 30, 2025 | 184,000.00 |
| Mar 31, 2025 | 68,000.00 |
| Mar 31, 2025 | 68,000.00 |
| Dec 31, 2024 | 81,000.00 |
| Dec 31, 2024 | 81,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 101,000.00 |
| Jun 30, 2024 | 101,000.00 |
| Mar 31, 2024 | 172,000.00 |
| Mar 31, 2024 | 172,000.00 |
| Dec 31, 2023 | 250,000.00 |
| Dec 31, 2023 | 250,000.00 |